Enantioselective biodegradation of pharmaceuticals, Alprenolol (cas 13655-52-2) and propranolol, by an activated sludge inoculum
-
Add time:09/07/2019 Source:sciencedirect.com
Biodegradation of chiral pharmaceuticals in the environment can be enantioselective. Thus quantification of enantiomeric fractions during the biodegradation process is crucial for assessing the fate of chiral pollutants. This work presents the biodegradation of Alprenolol (cas 13655-52-2) and propranolol using an activated sludge inoculum, monitored by a validated enantioselective HPLC method with fluorescence detection. The enantioseparation was optimized using a vancomycin-based chiral stationary phase under polar ionic mode. The method was validated using a minimal salts medium inoculated with activated sludge as matrix. The method was selective and linear in the range of 10–800 ng/ml, with a R2>0.99. The accuracy ranged from 85.0 percent to 103 percent, the recovery ranged from 79.9 percent to 103 percent, and the precision measured by the relative standard deviation (RSD) was <7.18 percent for intra-batch and <5.39 percent for inter-batch assays. The limits of quantification and detection for all enantiomers were 10 ng/ml and 2.5 ng/ml, respectively. The method was successfully applied to follow the biodegradation of the target pharmaceuticals using an activated sludge inoculum during a fifteen days assay. The results indicated slightly higher biodegradation rates for the S-enantiomeric forms of both beta-blockers. The presence of another carbon source maintained the enantioselective degradation pattern while enhancing biodegradation extent up to fourteen percent.
We also recommend Trading Suppliers and Manufacturers of Alprenolol (cas 13655-52-2). Pls Click Website Link as below: cas 13655-52-2 suppliers
Prev:Labeling of Alprenolol (cas 13655-52-2) with fluorescent aryl iodide as a reagent based on Mizoroki–Heck coupling reaction
Next:Electrophoretic behavior of Alprenolol (cas 13655-52-2) in mixed solvent electrolyte systems) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Combined pharmacokinetic and pharmacodynamic studies on Alprenolol (cas 13655-52-2) and 4-hydroxy-Alprenolol (cas 13655-52-2) in man09/27/2019
- Microcalorimetric studies on the complex formation between cellobiohydrolase I (CBH I) from Trichoderma reesei and the (R)- and (S)-enantiomers of the β-receptor blocking agent Alprenolol (cas 13655-52-2)09/26/2019
- Gel formulations containing catanionic vesicles composed of Alprenolol (cas 13655-52-2) and SDS: Effects of drug release and skin penetration on aggregate structure09/25/2019
- Regular paperAnalysis of the vasodilator action of Alprenolol (cas 13655-52-2)09/24/2019
- Nasal absorption of Alprenolol (cas 13655-52-2) and metoprolol09/10/2019
- Enantioselective determination of Alprenolol (cas 13655-52-2) in human plasma by liquid chromatography with tandem mass spectrometry using cellobiohydrolase chiral stationary phases09/09/2019
- Electrophoretic behavior of Alprenolol (cas 13655-52-2) in mixed solvent electrolyte systems09/08/2019
- Labeling of Alprenolol (cas 13655-52-2) with fluorescent aryl iodide as a reagent based on Mizoroki–Heck coupling reaction09/06/2019
- Quantification of Alprenolol (cas 13655-52-2) and propranolol in human plasma using a two-dimensional liquid chromatography (2D-LC)09/05/2019